Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Cash from Investing Activities: 2017-2019

Historic Cash from Investing Activities for Astria Therapeutics (ATXS) over the last 1 years, with Dec 2019 value amounting to -$3.5 million.

  • Astria Therapeutics' Cash from Investing Activities fell 420.29% to -$3.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.1 million, marking a year-over-year increase of 41.93%. This contributed to the annual value of -$191.9 million for FY2024, which is 242.07% down from last year.
  • As of Q4 2019, Astria Therapeutics' Cash from Investing Activities stood at -$3.5 million, which was down 125.67% from $13.7 million recorded in Q3 2019.
  • Over the past 5 years, Astria Therapeutics' Cash from Investing Activities peaked at $14.9 million during Q1 2017, and registered a low of -$23.0 million during Q3 2018.
  • Over the past 3 years, Astria Therapeutics' median Cash from Investing Activities value was $538,000 (recorded in 2017), while the average stood at -$1.4 million.
  • As far as peak fluctuations go, Astria Therapeutics' Cash from Investing Activities crashed by 127,716.67% in 2018, and later soared by 159.33% in 2019.
  • Astria Therapeutics' Cash from Investing Activities (Quarterly) stood at -$18,000 in 2017, then crashed by 127,716.67% to $1.1 million in 2018, then plummeted by 420.29% to -$3.5 million in 2019.
  • Its last three reported values are -$3.5 million in Q4 2019, $13.7 million for Q3 2019, and $3.5 million during Q2 2019.